Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19
<p><strong>Background</strong></p> Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patien...
Main Authors: | Lawler, PR, Goligher, EC, Berger, JS, Beane, A, Estcourt, LJ, Haniffa, R, Stanworth, SJ |
---|---|
其他作者: | ATTACC Investigators |
格式: | Journal article |
语言: | English |
出版: |
Massachusetts Medical Society
2021
|
相似书籍
-
Therapeutic anticoagulation with heparin in critically ill patients with Covid-19
由: Goligher, EC, et al.
出版: (2021) -
Continuation of therapeutic dose heparin for critically ill patients with COVID-19
由: Bradbury, CA, et al.
出版: (2023) -
Anticoagulation is the answer in treating noncritical COVID-19 patients
由: Kabir Azad A.
出版: (2021-10-01) -
Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
由: Francesco Poletto, et al.
出版: (2022-03-01) -
On supergravity and noncritical strings
由: Andrea Dei, et al.
出版: (2025-01-01)